Literature DB >> 2135735

Comparison of curietherapy versus external irradiation combined with curietherapy in stage II squamous cell carcinomas of the mobile tongue.

V Benk1, J J Mazeron, L Grimard, J Crook, E Haddad, P Piedbois, E Calitchi, M Raynal, M Martin, J P Le Bourgeois.   

Abstract

One hundred and ten patients with Stage II epidermoid carcinomas of the mobile tongue were treated by interstitial irradiation (Group I: 85 patients) or external irradiation to the primary and the regional lymphatics followed by an interstitial boost (Group II: 25 patients). The neck was managed by either an elective neck dissection (43 patients) completed by external irradiation in 13 patients with pathological specimen or close follow-up (40 patients) with therapeutic neck dissection for relapses (7 patients) in Group I. Primary local control was 88% in Group I and 36% in Group II. Regional control was 91% in Group I and 5/6 in Group II for patients whose primary tumor was controlled. Five-year absolute disease-free survival (DFS) was 42% in Group I and 24% in Group II, but there was an imbalance in the distribution of larger tumors favoring Group I. There were 30 radiation-induced complications and four patients required corrective surgery. This retrospective analysis showed better results in patients whose primary was treated by interstitial irradiation alone which has the extra advantage of preserving salivary function.

Entities:  

Mesh:

Year:  1990        PMID: 2135735     DOI: 10.1016/0167-8140(90)90114-c

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer.

Authors:  Lubos Tuček; Jiri Petera; Igor Sirák; Milan Vošmik; Helena Doležalová; Simona Brokešová; Miroslav Hodek; Linda Kašaová; Petr Paluska
Journal:  Rep Pract Oncol Radiother       Date:  2011-08-06

2.  High-dose-rate interstitial brachytherapy for mobile tongue cancer: preliminary results of a dose reduction trial.

Authors:  Hironori Akiyama; Ken Yoshida; Hideya Yamazaki; Tadashi Takenaka; Tadayuki Kotsuma; Koji Masui; Yasuo Yoshioka; Takumi Arika; Kimishige Shimizutani; Eiichi Tanaka
Journal:  J Contemp Brachytherapy       Date:  2014-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.